Chemistry:Rilmazafone
 | |
| Clinical data | |
|---|---|
| Trade names | Rhythmy |
| Other names | 5-([(2-aminoacetyl)amino]methyl)-1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-N,N-dimethyl-1,2,4-triazole-3-carboxamide |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral (tablets) |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 10.5 h |
| Excretion | Urine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C21H20Cl2N6O3 |
| Molar mass | 475.33 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Rilmazafone[1] (リスミー, Rhythmy, previously known as 450191-S) is a water-soluble prodrug developed in Japan.[2] Once metabolized, rilmazafone is converted into several benzodiazepine metabolites that have sedative and hypnotic effects.[3][4] These metabolites induce impairment of motor function and have hypnotic properties.[5]
Rilmazafone is not a benzodiazepine, since there is no benzene ring fused with a diazepine ring in the compound; in fact, the parent drug has no diazepine ring. It is therefore not classified as a benzodiazepine in several countries, including the United States, where it is not designated a controlled substance. Rilmazafone has no effects on benzodiazepine receptors itself, nor does it produce any psychoactive effects prior to metabolism. However, once inside the body it is metabolized by aminopeptidase enzymes in the small intestine to form the principal active benzodiazepine rilmazolam (8-chloro-6-(2-chlorophenyl)-N,N-dimethyl-4H-1,2,4-triazolo [1,5-a][1,4]benzodiazepine-2-carboxamide).[6][7] As can be seen in the molecular diagram below, the principal metabolite contains a benzodiazepine ring structure (i.e., a benzene ring fused with a diazepine ring), unlike the parent compound (rilmazafone), which has no diazepine ring.
See also
References
- ↑ DE Patent 2725164
- ↑ "[Pharmacological studies of a new sleep-inducer, 1H-1,2,4-triazolyl benzophenone derivatives (450191-S) (I). Behavioral analysis]" (in Japanese). Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 84 (1): 109–54. July 1984. doi:10.1254/fpj.84.109. PMID 6149174.
- ↑ "[Pharmacology of a new sleep inducer, 1H-1,2,4-triazolyl benzophenone derivative, 450191-S (II). Sleep-inducing activity and effect on the motor system]" (in Japanese). Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 84 (1): 25–89. July 1984. doi:10.1254/fpj.84.25. PMID 6149175.
- ↑ "[Pharmacology of a 1H-1, 2, 4-triazolyl benzophenone derivative (450191-S), a new sleep-inducer (III). Behavioral study on interactions of 450191-S and other drugs in mice]" (in Japanese). Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 84 (2): 155–73. August 1984. doi:10.1254/fpj.84.155. PMID 6149177.
- ↑ "[Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes]". Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology 25 (3): 143–51. June 2005. PMID 16045197.
- ↑ "Intestinal activation of a new sleep inducer 450191-S, a 1H-1,2,4-triazolyl benzophenone derivative, in rats". Journal of Pharmacobio-Dynamics 9 (3): 315–20. March 1986. doi:10.1248/bpb1978.9.315. PMID 3454653.
- ↑ "Comparative hepatic transport of desglycylated and cyclic metabolites of rilmazafone in rats: analysis by multiple indicator dilution method". Biopharmaceutics & Drug Disposition 14 (4): 279–90. May 1993. doi:10.1002/bdd.2510140402. PMID 8499579.
External links
- "リスミー'リルマザホン塩酸塩水和物錠 Rhythmy (rilmazafone hydrochloride hydrate, tablets) Prescribing Information." (in ja). Shionogi & Co., Ltd.. http://database.japic.or.jp/pdf/newPINS/00001601.pdf.
- Drug Information Sheet
 |  |
